Hopital Femme Mère Enfant
Bron, 69500, France
Location status: Recruiting
Location contact
Diane PINA
CONTACT
0633493731 ext. +33
Laurence LION FRANCOIS, MD,PhD
CONTACT
04 27 85 53 77 ext. +33
Laurence LION FRANCOIS, MD,PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05652101
Hereditary hyperekplexia is a rare neuronal disorder, caused by genetic defects leading to dysfunction of glycinergic neurotransmission.
The clinical presentation is characterized by stiffness and exaggerated startle responses to unexpected stimuli, that appear shortly after birth.
The generalised stiffness can lead to apnea and sudden infant death syndrome.
Several genes are known to be associated with hereditary hyperekplexia. The most frequent are Glycine Receptor Alpha 1 (GLRA1), Glycine Receptor Beta (GLRB) and Solute Carrier Family 6 Member 5 (SLC6A5). They encode for the postsynaptic glycine receptor (GLRA1, GLRB) and the presynaptic glycine transport (SLC6A5). Genetic mutations in these genes lead to dysfunction in the glycinergic inhibitory neurotransmission.
The neurodevelopment was initially described as normal, or as delayed due to the motor difficulties. Global development delay and intellectual disability are reported as well, in the most recent studies.
Nevertheless, the degree of severity of the learning difficulties and the adaptive faculties of the patients is not specified.
Similarly, the efficacy of clonazepam in hyperekplexia is well known, but the evolution of dosage over time and the frequency of complete withdrawal have never been studied.
The primary endpoint of this study is to describe adaptive skills using a standardized questionnaire, Vineland Adaptive Behavior Scale (VABS2).
Secondary endpoints are:
* Neurodevelopmental course study * Description of the evolution of the clinical manifestations over the years * Evaluation of the efficacity of the treatment CLONAZEPAM, initially and over time, and evolution of the dosage * Comparison of clinical and therapeutical characteristics according to the genotype
Interested in participating?
Request Info2 year and older
All sexes
Observational
Bron, 69500, France
Location status: Recruiting
Diane PINA
CONTACT
0633493731 ext. +33
Laurence LION FRANCOIS, MD,PhD
CONTACT
04 27 85 53 77 ext. +33
Laurence LION FRANCOIS, MD,PhD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The data collected concerns:
This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.
Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose.
Time frame: maximum 2 months after the inclusion
The VABS2 measures adaptative scores in the fields of :
The domains are made up of subdomains in which the scores are added to form the domain composite scores. The four domain composite scores then combine to form the adaptive behaviour composite for those individuals aged birth to 6 years 11 months. Three domain composite scores (communication, daily living skills and socialization) combine to form the adaptive behaviour composite for those aged 7 through 90.
The results are expressed with standard scores, percentile ranks, adaptive levels and age equivalents.
Contact information is provided by the study sponsor or research team.
Diane PINA
CONTACT
0633493731 ext. +33
Laurence LION FRANCOIS, MD,PhD
CONTACT
04 27 85 53 77 ext. +33
Hospices Civils de Lyon
Other
Study of Adaptative Skills and Neurodevelopmental Trajectory for Patients With Hyperekplexia (Startle Disease)
Acronym: StarDev
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05168969
CTNNB1 Gene Mutation, Central Nervous System Diseases
Saint-Etienne, France
View Trial DetailsNCT01829724
Brain Damage, Chronic, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07082725
Brain Diseases, Brain Diseases, Metabolic
Oakland, California, United States
View Trial DetailsNCT06857006
Brain Diseases, Brain Metastases
Birmingham, Alabama, United States
View Trial Details